Outlook Therapeutics Reports Material Agreement, Equity Sales

TL;DR

**Outlook Therapeutics just made a big financial move, likely involving new debt or selling more shares.**

AI Summary

Outlook Therapeutics, Inc. filed an 8-K on January 24, 2024, reporting an event that occurred on January 22, 2024, related to an entry into a material definitive agreement, creation of a direct financial obligation, and unregistered sales of equity securities. This filing indicates potential new financing or strategic moves, which could impact the company's financial health and future prospects. For investors, this matters because such agreements often involve diluting existing shares or taking on debt, which can affect share price and long-term value.

Why It Matters

This filing signals that Outlook Therapeutics has entered into significant financial arrangements, potentially impacting its capital structure and future operational funding. Investors should monitor the details of these agreements as they could lead to share dilution or increased debt obligations.

Risk Assessment

Risk Level: medium — The filing indicates new financial obligations and unregistered sales of equity, which often carry risks of dilution for existing shareholders or increased debt burden for the company.

Analyst Insight

A smart investor would await further details on the 'Material Definitive Agreement' and 'Unregistered Sales of Equity Securities' to assess potential dilution or debt impact before making any investment decisions.

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 22, 2024 (date) — date of the earliest event reported
• January 24, 2024 (date) — date the 8-K was filed
• 001-37759 (other) — Commission File Number
• Delaware (other) — State of incorporation for Outlook Therapeutics, Inc.

FAQ

Key Financial Figures

• $60 million — he "Private Placement") an aggregate of $60 million in shares (the "Shares") of the Company
• $0.01 — f the Company's common stock, par value $0.01 per share (the "Common Stock"), and, fo
• $0.35 — rrant will be equal to the lower of (a) $0.35 and (b) the Market Price of the Common
• $0.07 — the Closing (but in no event lower than $0.07 per share). The Warrants will have a p
• $1.00 — P of the Common Stock equals or exceeds $1.00 per share (subject to adjustment in the
• $99 million — ng, and may receive up to an additional $99 million of gross proceeds upon cash exercise of
• $16.1 million — gregate purchase price of approximately $16.1 million. The foregoing descriptions of the Sec
• $5 million — ant to which Syntone agreed to purchase $5 million of shares of Common Stock (the "Syntone
• $31.8 million — ber 22, 2022 in the principal amount of $31.8 million (as previously amended, the "Note"). Pu
• $15.0 million — nitial conversion price with respect to $15.0 million in aggregate principal amount of the No
• $25.0 million — in aggregate gross proceeds of at least $25.0 million (a "Qualified Offering") (which the Com
• $3.0 million — gation of the Company to repay at least $3.0 million of the outstanding balance of the Note

Filing Documents

• tm243921d1_8k.htm (8-K) — 55KB
• tm243921d1_ex4-1.htm (EX-4.1) — 115KB
• tm243921d1_ex4-2.htm (EX-4.2) — 115KB
• tm243921d1_ex10-1.htm (EX-10.1) — 279KB
• tm243921d1_ex10-2.htm (EX-10.2) — 55KB
• tm243921d1_ex10-3.htm (EX-10.3) — 143KB
• tm243921d1_ex10-4.htm (EX-10.4) — 266KB
• tm243921d1_ex10-5.htm (EX-10.5) — 139KB
• tm243921d1_ex10-6.htm (EX-10.6) — 26KB
• tm243921d1_ex99-1.htm (EX-99.1) — 25KB
• image_001.jpg (GRAPHIC) — 4KB
• 0001104659-24-006019.txt ( ) — 1671KB
• otlk-20240122.xsd (EX-101.SCH) — 3KB
• otlk-20240122_lab.xml (EX-101.LAB) — 34KB
• otlk-20240122_pre.xml (EX-101.PRE) — 22KB
• tm243921d1_8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. On January 23, 2024, the Company issued a press release announcing the Private Placement, Syntone Private Placement and Note Amendment. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "expect," "intend," "may," "will," "would," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements, including without limitation statements regarding the expected closing of the Private Placement and the Syntone Private Placement, the Company's receipt of the necessary stockholder approval, Sytone's receipt of the necessary regulatory approvals, anticipated proceeds from the Private Placement and Syntone Private Placement and the use thereof, the Company's plans to file registration development plans with respect to its product candidates, including the planned NORSE EIGHT clinical trial, and the effectiveness of the Conditional Amendments. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this Current Report on Form 8-K. These forward-looking statements are subject to risks and uncertainties that could cause results and events to differ significantly from those expressed or implied by the forward-looking statements, including risks associated with receipt of necessary stockholder approvals and closing a securities offering. Additional factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this Current Report on Form 8-K are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including under "Risk Factors" in the Company's annual report

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 4.1 Form of Warrant 4.2 Form of Syntone Warrant 10.1 Form of Securities Purchase Agreement 10.2 Form of Support Agreement 10.3 Form of Registration Rights Agreement. 10.4 Syntone Purchase Agreement, dated January 22, 2024 10.5 Syntone Registration Rights Agreement, dated January 22, 2024 10.6 Third Amendment to Convertible Promissory Note, dated January 22, 2024 99.1 Press Release dated January 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: January 24, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR